Tessera Defense and Homeland Security Inc. (HLSQ) is a NYSE American-listed physical security technology company that operates a unified platform connecting cameras, sensors, detection technologies, artificial intelligence and other security infrastructure. News related to Tessera often focuses on how the company develops and deploys integrated security solutions for homeland security, critical infrastructure, energy, digital infrastructure and enterprise environments.
Coverage of Tessera can include announcements about enhancements to its unified security platform, updates on deployments that connect detection, intelligence and response across complex sites, and developments involving its subsidiaries. Zorronet, which provides AI-powered security intelligence and autonomous command-and-control capabilities, and DFSL, which develops LADAR-based counter-UAS and perimeter security systems, may feature in reports about advanced sensing, real-time intelligence and autonomous response applications.
Another important theme in Tessera-related news is its corporate evolution. On September 11, 2026, the company changed its legal name from BiomX Inc. to Tessera Defense and Homeland Security Inc. and began trading under the HLSQ ticker, replacing PHGE. Articles and releases may reference this transition and explain that older items under the BiomX name or PHGE symbol document the issuer’s former biotechnology business rather than its current security focus.
Investors, analysts and security professionals following Tessera’s news can expect information about platform capabilities, customer segments such as critical infrastructure and homeland security organizations, and the company’s role in addressing evolving physical threats, including those involving unmanned and autonomous systems. Historical news under the BiomX identity remains part of the record but should be interpreted in light of the company’s subsequent shift to physical security technology.
BiomX (NYSE American: PHGE) announced the publication of a scientific paper on the Exodus algorithm, enhancing the identification of genetically-related microorganisms. The Exodus algorithm improves the quantification of pooled genomes, achieving median error rates between 0% and 0.21%. Notably, the algorithm recorded no false negatives, indicating high accuracy even with low-abundance genomes. This advancement is expected to optimize the detection of virus variants and aid in the analysis of various genomic projects.
BiomX (PHGE) has made significant strides in its pipeline, particularly in treating cystic fibrosis (BX004) and atopic dermatitis (BX005). The Phase 1b/2a trial for BX004 is set to begin, with initial results expected by Q3 2022. The IND for BX005 has been approved, with data readouts anticipated in Q4 2022. Financially, the company reported a cash balance of $55.7 million as of March 31, 2022, down from $63.1 million, primarily due to operating expenses. Despite a net loss of $8.2 million, the cash runway is projected to last through 2023.
BiomX Inc. (NYSE American: PHGE) will host a virtual key opinion leader webinar on May 12, 2022, at 11:00 AM EDT to discuss BX004, a phage therapy aimed at treating Pseudomonas Aeruginosa infections in cystic fibrosis patients. The FDA cleared BX004 for a Phase 1b/2a trial in September 2021, with initial data expected in Q3 2022. Key Opinion Leaders Dr. Dave Nichols and Dr. Saima Aslam will present, followed by BiomX CEO Jonathan Solomon. Registration is available on BiomX's website.
BiomX (NYSE American: PHGE) will host a conference call on May 11, 2022, at 8:00 a.m. EDT to report first quarter 2022 financial results and provide business updates. BiomX is a clinical-stage microbiome company that focuses on developing natural and engineered phage therapies to combat chronic diseases, including cystic fibrosis and colorectal cancer. Interested parties can participate via a dedicated dial-in or through a live audio webcast available on the company’s website.
BiomX (NYSE: PHGE) reported its financial results for Q4 and the full year 2021, revealing a cash position of $63.1 million, up from $57.1 million in 2020. The company anticipates major clinical data readouts in 2022 for its cystic fibrosis (BX004) and atopic dermatitis (BX005) therapies. BiomX’s current cash runway supports operations through 2023, with potential for extension to mid-2024 via venture debt. The net loss for 2021 stood at $36.2 million, marking an increase from $30.1 million in 2020. A conference call is scheduled for today at 8:00 am ET.
BiomX Inc. (NYSE American: PHGE) has announced a conference call scheduled for March 30, 2022, at 8:00 a.m. EDT to discuss its fourth quarter and full year 2021 financial results along with business updates. The company specializes in developing natural and engineered phage therapies targeting bacteria linked to chronic diseases like cystic fibrosis and colorectal cancer. Investors can access the live webcast via biomx.com.
BiomX (NYSE American: PHGE) has announced that CEO Jonathan Solomon will present at three notable conferences in 2022. These include the Aegis Virtual Conference on February 24, the Chardan 4th Annual Microbiome Medicines Summit on March 1, and the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 17. The presentations will highlight the company's development of innovative phage therapies targeting pathogenic bacteria related to various chronic diseases. Live webcasts will be available on BiomX's website.
BiomX (AMEX: PHGE) has announced a $5 million funding from the Cystic Fibrosis Foundation to support its Phase 1b/2a study of BX004, targeting chronic respiratory infections in cystic fibrosis patients. The funding will be provided in two tranches: an initial $3 million received in December 2021 and a potential additional $2 million upon completion of patient dosing. The study aims to assess the therapy's safety and efficacy, with results expected in 2022.
BiomX Inc. (PHGE), a clinical-stage microbiome company, announced its participation in two upcoming healthcare events: the Jefferies London Healthcare Conference from November 18-19, 2021 and the 2021 Phage Futures Congress Europe on November 23-24, 2021. At the Jefferies conference, an on-demand session will be presented by Jonathan Solomon, available from November 18. The Phage Futures Congress will feature a presentation titled “Nebulized Bacteriophage Therapy” by Myriam Golembo, Ph.D. on November 23. Webcasts will be accessible via the company's website.
BiomX (PHGE) announced a strategic shift to focus on its cystic fibrosis and atopic dermatitis programs, aiming for proof-of-concept data in 2022. The company has extended its cash runway to the end of 2023, supported by FDA clearance for its Phase 1b/2a trial in cystic fibrosis. BiomX will discontinue its acne program and postpone developments in inflammatory bowel disease and colorectal cancer.
As of September 30, 2021, BiomX reported a cash balance of $68.3 million and a net loss of $10 million for Q3 2021.